We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Vera Bril

Vera Bril BSc, FRCPC, MD

Professor of Medicine (Neurology), University of Toronto, and Director of the Neuromuscular Section, Division of Neurology, University of Toronto and University Health Network, Toronto, Canada

Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of the Neuromuscular Section, Division of Neurology, University of Toronto and University Health Network. She served as the division director of Neurology at University Health Network and Sinai Health System from 2005-2019. She has particular expertise in the diagnosis and management of patients with complex neuromuscular disorders. Her research interests have centered on the diagnosis and evidence-based treatment of myasthenia gravis, inflammatory polyneuropathies, and diabetic sensorimotor polyneuropathy. Her work has helped set the standards for electrophysiological investigations in the definition and evaluation of the progression of chronic polyneuropathies. Her research has helped establish the role of intravenous immunoglobulin in the treatment of myasthenia gravis and the Guillain-Barré Syndrome, and the long-term treatment of chronic inflammatory demyelinating polyneuropathy. She has acted in an advisory capacity to Health Canada and the FDA.

Disclosures

Dr. Bril is a consultant for Argenx, Takeda, CSL, Alnylam, Akcea, Ionis, Grifols, Sanofi, Immunovant, UCB, and Momenta. She receives research support from Argenx, Takeda, CSL, Akcea, Ionis, Grifols, Immunovant, UCB, and Momenta.